Literature DB >> 2116665

Two G protein oncogenes in human endocrine tumors.

J Lyons1, C A Landis, G Harsh, L Vallar, K Grünewald, H Feichtinger, Q Y Duh, O H Clark, E Kawasaki, H R Bourne.   

Abstract

Somatic mutations in a subset of growth hormone (GH)-secreting pituitary tumors convert the gene for the alpha polypeptide chain (alpha s) of Gs into a putative oncogene, termed gsp. These mutations, which activate alpha s by inhibiting its guanosine triphosphatase (GTPase) activity, are found in codons for either of two amino acids, each of which is completely conserved in all known G protein alpha chains. The likelihood that similar mutations would activate other G proteins prompted a survey of human tumors for mutations that replace either of these two amino acids in other G protein alpha chain genes. The first gene so far tested, which encodes the alpha chain of Gi2, showed mutations that replaced arginine-179 with either cysteine or histidine in 3 of 11 tumors of the adrenal cortex and 3 of 10 endocrine tumors of the ovary. The mutant alpha i2 gene is a putative oncogene, referred to as gip2. In addition, gsp mutations were found in 18 of 42 GH-secreting pituitary tumors and in an autonomously functioning thyroid adenoma. These findings suggest that human tumors may harbor oncogenic mutations in various G protein alpha chain genes.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2116665     DOI: 10.1126/science.2116665

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  186 in total

1.  Mutations in the gene encoding the alpha-subunit of the Gs protein in molar pregnancy.

Authors:  G Garon; J G LeHoux; P Bessette
Journal:  Endocrine       Date:  1999-08       Impact factor: 3.633

2.  Expression profiles of 290 ESTs mapped to chromosome 3 in human epithelial ovarian cancer cell lines using DNA expression oligonucleotide microarrays.

Authors:  Emily N Manderson; Anne-Marie Mes-Masson; Jaroslav Novak; Peter D Lee; Diane Provencher; Thomas J Hudson; Patricia N Tonin
Journal:  Genome Res       Date:  2002-01       Impact factor: 9.043

Review 3.  Thyrotropin receptor mutations in thyroid diseases.

Authors:  P M Yen
Journal:  Rev Endocr Metab Disord       Date:  2000-01       Impact factor: 6.514

Review 4.  Clinical spectrum and pathogenesis of pseudohypoparathyroidism.

Authors:  M A Levine
Journal:  Rev Endocr Metab Disord       Date:  2000-11       Impact factor: 6.514

5.  MOD-D, a Galpha subunit of the fungus Podospora anserina, is involved in both regulation of development and vegetative incompatibility.

Authors:  G Loubradou; J Bégueret; B Turcq
Journal:  Genetics       Date:  1999-06       Impact factor: 4.562

6.  GNAS mutations in primary mucinous and non-mucinous lung adenocarcinomas.

Authors:  Lauren L Ritterhouse; Marina Vivero; Mari Mino-Kenudson; Lynette M Sholl; A John Iafrate; Valentina Nardi; Fei Dong
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

7.  The p53 tumor suppressor targets a novel regulator of G protein signaling.

Authors:  L Buckbinder; S Velasco-Miguel; Y Chen; N Xu; R Talbott; L Gelbert; J Gao; B R Seizinger; J S Gutkind; N Kley
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

8.  Tyrosine phosphorylation of G protein alpha subunits by pp60c-src.

Authors:  W P Hausdorff; J A Pitcher; D K Luttrell; M E Linder; H Kurose; S J Parsons; M G Caron; R J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-01       Impact factor: 11.205

9.  Mutations that rescue the paralysis of Caenorhabditis elegans ric-8 (synembryn) mutants activate the G alpha(s) pathway and define a third major branch of the synaptic signaling network.

Authors:  Michael A Schade; Nicole K Reynolds; Claudia M Dollins; Kenneth G Miller
Journal:  Genetics       Date:  2004-10-16       Impact factor: 4.562

10.  Aberrations of growth factor control in metastatic follicular thyroid cancer in vitro.

Authors:  T Hoelting; A Zielke; A E Siperstein; O H Clark; Q Y Duh
Journal:  Clin Exp Metastasis       Date:  1994-07       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.